CSDE1 Drives Glycolysis and the Progression of Prostate Cancer Through RAC1-Dependent RAS/MAPK Activation - PubMed
14 hours ago
- #RAC1-MAPK
- #prostate-cancer
- #CSDE1
- CSDE1 is upregulated in prostate cancer (PCa) tissues and linked to poorer progression-free survival in high Gleason score patients.
- CSDE1 knockdown reduces PCa cell proliferation, migration, invasion, and metabolic activity (lower ECAR, OCR, lactate production).
- CSDE1 interacts with RAC1, influencing RAC1-related signaling and MAPK pathway phosphorylation.
- RAC1 modulation partially reverses CSDE1-associated cellular and metabolic effects.
- CSDE1 expression increases glycolytic regulators GLUT1 and LDHA; MAPK inhibition attenuates glycolytic changes.
- In vivo studies confirm the oncogenic role of the CSDE1-RAC1 axis in tumor growth.
- CSDE1 enhances RAC1-mediated MAPK signaling and metabolic reprogramming in PCa, suggesting its potential as a biomarker/therapeutic target.